Navigation Links
New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
Date:11/19/2008

EXTON, Pa., Nov. 19 /PRNewswire/ -- BioTrends Research Group, Inc. released its first TreatmentTrends(TM): Canadian Nephrology Report. This report runs parallel to two ongoing studies BioTrends conducts -- TreatmentTrends(TM): US and European Nephrology. The report is based on the results of an on-line survey completed by 40 Canadian Nephrologists and focuses on the management of renal anemia and hyperphosphatemia.

In the anemia market, Amgen's Aranesp is the market share leader among patients with Chronic Kidney Disease not on dialysis (CKD) whereas share between Aranesp and Eprex in the dialysis market is more evenly divided. Satisfaction between brands is similar, but Eprex has a perceived competitive advantage on achieving target hemoglobin levels quickly and allowing for easy dosing modifications. Aranesp, on the other hand, has a perceived advantage when it comes to extended dosing intervals, an attribute that is considered more important in CKD than in dialysis. No significant shifts in projected use of ESAs or in ESA market share are expected in the next six months. Unaided awareness of new ESAs in development is very low. Of those who are aware, Roche's Mircera is most often mentioned.

Use of IV iron is limited outside of hemodialysis with less than 20% of peritoneal dialysis, less than 15% of Stage 4 CKD and less than 5% of Stage 3 CKD patients receiving therapy. American Regent's Venofer is the market share leader in both dialysis and CKD, but their margin over Watson's Ferrlecit is greater in CKD. Company contact through sales representatives is virtually non-existent for all the IV iron players with almost 100% of Nephrologists reporting no contact in more than three months, and often never. The IV iron market is expected to stay relatively stagnant in the next six months.

In the phosphate binder market, calcium carbonate continues to be the binder used in the vast majority of CKD and dialysis patients, a decision that seems primarily driven by cost / reimbursement. Familiarity with Genzyme's Renagel is high, as are perceptions of its performance on the most important phosphate binder attributes, but use of the product tends to be limited to second line therapy. Current share for Shire's Fosrenol is relatively low but Nephrologists project a significant increase in use to close to 10% market share in the dialysis setting in the next six months, with decreases projected for both calcium-based binders and Renagel. Current use of FMC's PhosLo is also low, but Nephrologists expect increases in use among both dialysis and CKD patients in the next six months. Calcium carbonate, however, is expected to remain the go to calcium-based binder with approximately 90% of the calcium business.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Gina Negrette, a ... more than a decade of experience in psychiatry, treating clients in diverse settings, ... eating disorders, psychotic and manic conditions, as well as those who were fighting ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... for its Product Innovation in the prestigious CEO World Awards®. The coveted annual ... new products and services, CEO case studies, corporate social responsibility, and milestones from ...
(Date:7/24/2017)... ... ... Engineers at the University of Maryland have invented an entirely new kind of ... the body uses. , In ordinary batteries the electrical energy, or current, delivered ... battery is generated by moving positive ions from one end to the other of ...
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS ... Institute (SLMBNI), part of Saint Luke’s Health System . Dr. Upadhyaya has ... Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., who has served ...
(Date:7/24/2017)... CA (PRWEB) , ... July 24, 2017 , ... Cosmetic ... spotlight doctors and the cosmetic surgeries they perform on a daily basis. , ... the cosmetic surgery procedures they specialize in at their practices. , When asked ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of Diplomat ... families to thrive on nutrition support. To celebrate its anniversary, ... site has a fresh new look with improved organization to create the ... ... "We,ve ...
(Date:7/5/2017)... 5, 2017 Pace Analytical, a company of over 2,000 employees and ... have acquired ESC Lab Sciences, further solidifying their position as the top American ... . ... and CEO of Pace Analytical ... out of Mt Juliet, TN , enhances Pace Analytical,s capability ...
(Date:6/30/2017)... 2017 In vitro diagnostics market firm Kalorama ... at least ten diagnostic companies have successfully completed financings.  ... and a loan facility.  The size of these financings ... Kalorama Information provides a monthly IVD Market Trends ... Center. "Diagnostics ...
Breaking Medicine Technology: